Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Matthew Leonard

Physician Assistant Baltimore, MD Physician Assistant

NPI 1699846071 CMS profile 11091995

4940 Eastern Ave, Baltimore, MD 21224

Open in the dashboard

General payments

$4,439

204 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Leonard of Baltimore, MD is reported in the CMS Open Payments database as having received $4,439 across 204 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $421 21
2024 General $1,296 69
2023 General $1,205 54
2022 General $1,289 53
2021 General $227 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Leonard
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Matthew Leonard were reported at $421. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Matthew Leonard Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $227 $132 $37–$438 $132
2022 $1,289 $155 $48–$522 $149
2023 $1,205 $167 $52–$557 $160
2024 $1,296 $178 $55–$600 $164
2025 $421 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Lundbeck LLC $719 37 payments
  2. Otsuka America Pharmaceutical, Inc. $709 23 payments
  3. AbbVie, Inc. $563 29 payments
  4. ITI, Inc. $414 19 payments
  5. Alkermes, Inc. $352 15 payments
  6. Tris Pharma Inc $352 23 payments
  7. Neurocrine Biosciences, Inc. $324 13 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $266 11 payments
  9. Teva Pharmaceuticals USA, Inc. $149 7 payments
  10. Corium, Inc. $139 7 payments
  11. Other $453 20 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,439 204 payments
Products named General payments · program years 2021–2025
  1. REXULTI Psychiatry $606 19 payments
  2. REXULTI Psychiatry $576 27 payments
  3. VRAYLAR $494 25 payments
  4. CAPLYTA $414 19 payments
  5. LYBALVI $352 15 payments
  6. Dyanavel XR $352 23 payments
  7. INGREZZA $302 12 payments
  8. ARISTADA Cns $283 12 payments
  9. ARISTADA Cns $283 12 payments
  10. ABILIFY MAINTENA $278 15 payments
  11. Other $2,140 94 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

1,124

Median for Physician Assistant: 241

Drug cost

$80,902

Median for Physician Assistant: $4,110

Branded share of claims

17%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trintellix Vortioxetine Hydrobromide Brand 40 $30,078
Vraylar Cariprazine Hcl Brand 12 $17,511
Rexulti Brexpiprazole Brand 11 $15,864
Aripiprazole Generic 36 $2,354
Quetiapine Fumarate Generic 93 $1,989
Clonazepam Generic 142 $1,690
Perphenazine Generic 17 $1,656
Alprazolam Generic 56 $1,509
Bupropion Xl Bupropion Hcl Brand 44 $876
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 22 $826

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Lundbeck LLC $182
  • Otsuka America Pharmaceutical, Inc. $82
$264 11 —
VRAYLAR
  • AbbVie, Inc. $162
$162 12 —
Dyanavel XR
  • Tris Pharma Inc $149
$149 — —
CAPLYTA
  • ITI, Inc. $131
$131 — —
ARISTADA
  • Alkermes, Inc. $122
$122 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

204 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record